XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM).

CANGZHOU,China,Feb. 13,2025-- A news report from xinhuanet: The Year of the Snake ushers in an energetic Spring Festival in Cangzhou,Hebei Province. Locals and tourists alike are reveling in the festi

The Only Forbes-Starred Hotel in Xiamen XIAMEN,China,Feb. 13,2025--Conrad Xiamen proudly announces its Four-Star recognition in the 2025 Forbes Travel Guide,making it the only hotel in Xiamen to recei

NEW YORK,Feb. 13,2025-- Accropeutics Inc. (Accropeutics),a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell deat

As a reminder,Aquarius\' innovative systems generate and supply clean electricity,designed to enable ultra-fast charging for electric vehicles in the rapidly growing EV market. Aquarius\' systems are

PHILADELPHIA and PERTH,Australia,Feb. 14,2025--Arcadium Lithium plc (NYSE: ALTM,ASX: LTM,"Arcadium Lithium"),a leading global lithium chemicals producer,has now received all required pre-cl